XML 70 R52.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Acquisitions (Narrative) (Details) $ / shares in Units, $ in Millions |  |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Dec. 27, 2023 USD ($) | Jan. 22, 2021 USD ($) | Dec. 31, 2022 USD ($) right $ / shares | Jan. 31, 2021 USD ($) right $ / shares | Dec. 31, 2023 USD ($) $ / shares | Dec. 31, 2022 USD ($) $ / shares | Dec. 31, 2021 USD ($)
Business Acquisition [Line Items] |  |  |  |  |  |  |
Acquired in-process research and development (Note 3) |  |  |  |  | $ 3,799.8 | $ 908.5 | $ 970.1
Acquired IPR&D Expense |  |  |  |  |  | $ 333.8 |
Biopharma Global Inc |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Business acquisition, share price (in dollars per share) | $ / shares |  |  |  |  | $ 12.50 |  |
Cash paid, net of cash acquired | $ 1,035.8 |  |  |  |  |  |
Akouos Acquisition |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Business acquisition, share price (in dollars per share) | $ / shares |  |  | $ 12.50 |  |  | $ 12.50 |
Cash paid, net of cash acquired |  |  | $ 327.2 |  |  |  |
Consideration transferred, number of contingent value rights | right |  |  | 1 |  |  |  |
Contingent value right, additional price per share (in dollars per share) | $ / shares |  |  | $ 3.00 |  |  | $ 3.00 |
Contingent value right, additional price per share, aggregate amount |  |  | $ 122.0 |  |  | $ 122.0 |
Prevail Therapeutics Inc. |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Business acquisition, share price (in dollars per share) | $ / shares |  |  |  | $ 22.50 |  |  |
Cash paid, net of cash acquired |  | $ 747.4 |  | $ 747.4 |  |  |
Consideration transferred, number of contingent value rights | right |  |  |  | 1 |  |  |
Contingent value right, additional price per share (in dollars per share) | $ / shares |  |  |  | $ 4.00 |  |  |
Contingent value right, additional price per share, aggregate amount |  |  |  | $ 160.0 |  |  |
Contingent value right, monthly reduction | $ / shares |  |  |  | $ 0.083 |  |  |

X
- Definition Business Acquisition, Contingent Value Right, Additional Price Per Share + References No definition available. + Details
Name: | lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare
Namespace Prefix: | lly_
Data Type: | dtr-types1:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs + References No definition available. + Details
Name: | lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction
Namespace Prefix: | lly_
Data Type: | dtr-types1:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Business Combination, Consideration Transferred, Number Of Contingent Value Rights + References No definition available. + Details
Name: | lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights
Namespace Prefix: | lly_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payments for Asset Acquisitions + References No definition available. + Details
Name: | lly_PaymentsForAssetAcquisitions
Namespace Prefix: | lly_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5 + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionSharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_PointBiopharmaGlobalIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_AkouosAcquisitionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |